Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy
Science Advances · 2025-08 · 11 (31)
DOI: 10.1126/sciadv.adw5133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025-08. Verfasst von Cheng Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education and Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Med…. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, Biomimetics, Alveolar Epithelial Cells, Inflammation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Acute respiratory distress syndrome (ARDS) is a lethal respiratory condition, while effective pharmacological treatments remain elusive. We identified the decreased mechanical capacity and impaired proliferation of alveolar type 2 (AT2) epithelial cells in the inflammatory environment as the primary contributors to respiratory failure of ARDS. A biomimetic, self-adaptive, 7,8-dihydroxyflavone–loaded hollow mesoporous cerium oxide coated with a platelet membrane (HCeO x -D@PM) was developed for precise ARDS therapy. HCeO x -D@PM comprises a platelet membrane (PM) shell for targeted delivery to injured lungs and an HCeO x core, which enables high drug loading, efficient reactive oxygen species (ROS) scavenging, and penetration of the alveolar-capillary barrier. Initially, HCeO x -D@PM suppresses the inflammation and mitigates the adverse effects of lesions on AT2 cell by scavenging accumulated ROS. It then adaptively releases 7,8-dihydroxyflavone in response to cysteine–aspartic acid protease 3 activation, facilitating AT2 cell proliferation and notably improving survival rates in vivo, offering a promising advancement in the precise treatment of respiratory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education and Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang 550004, China.
- Institute of Burn Research, Southwest Hospital, State Key Lab of Trauma and Chemical Poisoning, Army Medical University (Third Military Medical University of Chinese P.L.A.), Chongqing 400038 China.
- Department of Respiratory and Critical Care Medicine, The First People's Hospital of Guiyang, Guiyang 550002, China.
- Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, Sichuan 637000, China.
- Department of Dermatology, Children' s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders,…
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China.
ORCID-Profile: Cheng Chen, Danfeng He, Xilan Li, Zhengwei Mao, Xiaolan Qi, Jun Deng
Zitieren
APA
Chen, C., He, D., Li, X., Ou, Z., Wang, H., Shou, Z., Wang, L., Mao, Z., Qi, X., & Deng, J. (2025). Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy. Science Advances, 11(31). https://doi.org/10.1126/sciadv.adw5133
Vancouver
Chen C, He D, Li X, Ou Z, Wang H, Shou Z, et al. Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy. Science Advances. 2025;11(31). doi:10.1126/sciadv.adw5133
BibTeX
@article{Chen2025,
author = {Chen, Cheng and He, Danfeng and Li, Xilan and Ou, Zelin and Wang, Hong and Shou, Zhinan and Wang, Li and Mao, Zhengwei and Qi, Xiaolan and Deng, Jun},
title = {Biomimetic targeted self-adaptive nanodrug for inflammation optimization and AT2 cell modulation in precise ARDS therapy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {31},
doi = {10.1126/sciadv.adw5133}
}
EUVIMED